Latest News and Press Releases

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Dublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "Invasive Ductal Carcinoma Treatment Market by Therapy, by Type, by Distribution Channel, and By Region" report has been added to ...

Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "NUT Midline Carcinoma Treatment Market by Treatment, by Route of Administration, by End-User, and By Region" report has been added to ...

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.Demographics and...

Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.Bladder cancer (International Classification...

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc